Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis
RWE closely aligns with FLAURA results, suggesting even greater benefit of first-line osimertinib in the real-world setting.
Authors
- Silvia Terezova (ORCID: https://orcid.org/0009-0008-3338-1125)
- Jeliazko Arabadjiev (ORCID: https://orcid.org/0000-0003-2440-2760)
- Assen Dudov (ORCID: https://orcid.org/0009-0008-4678-8629)
- Manoela Manova (ORCID: https://orcid.org/0000-0002-8749-7974)
- Daniel Penchev (ORCID: https://orcid.org/0009-0001-9971-9466)
- Boryana Ivanova (ORCID: https://orcid.org/0000-0003-2466-9254)
- Boryana Zidarova (ORCID: https://orcid.org/0009-0007-2081-7498)
- Radoslav Mangaldzhiev (ORCID: https://orcid.org/0000-0002-1109-6808)
- Dimitrina Apostolova (ORCID: https://orcid.org/0009-0008-5329-6411)
- M A Vasil'eva (ORCID: https://orcid.org/0009-0006-8354-3079)
- Alexandra Savova (ORCID: https://orcid.org/0000-0003-4579-5524)
- Lyubomir Bakalivanov (ORCID: https://orcid.org/0009-0008-8021-6640)
- Zornitsa Katrandzhieva
Institutions
- Qinetiq (United Kingdom) (GB)
- University of National and World Economy (BG)
- Tokuda Hospital (BG)
- Medical University of Sofia (BG)
- Acibadem City Clinic (BG)
- National Heart Hospital (BG)
- National Specialized Hospital for Active Treatment of Hematologic Diseases (BG)
- National AIDS Council (ZW)
- Acıbadem Adana Hospital (TR)
- National Center of Infectious and Parasitic Diseases (BG)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1080/14737167.2025.2535636
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00